Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3238 - The role of ABO blood groups in glial neoplasia


09 Oct 2016


Poster display


Ali Alkan


Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367


A. Alkan1, G. Yazıcı2, M. Cengiz2, İ. Çelik3, A. Kars3, F. Zorlu2

Author affiliations

  • 1 Medical Oncology, Ankara University Medical School-Cebeci Hastaneleri Tıbbi Onkoloji, 06590 - Ankara/TR
  • 2 Radiation Oncology, Hacettepe University Faculty of Medicine, 06590 - Ankara/TR
  • 3 Medical Oncology, Hacettepe University Faculty of Medicine, 06590 - Ankara/TR


Abstract 3238


There are numerous diseases that are claimed to have a correlation with ABO blood groups. The association with malignancy, especially with exocrine pancreas malignancy, has been documented. Analysis on distribution of blood groups in primary brain tumors and clinical value has revealed conflicting results. Here we aimed to evaluate the association between blood groups and glial neoplasia.


Patients admitted between 2000–2013 and had a diagnosis of glial neoplasia were evaluated. Documented blood groups were analyzed and compared with the National blood group data obtained from Turkish Red Crescent Society. The prognostic significance of ABO blood groups was analyzed within glioblastoma multiforme (GBM), anaplastic astrocytoma and grade 1-2 astrocytoma.


759 patients with a diagnosis of glial neoplasia were evaluated. Distribution of ABO blood groups in the different grades of glial neoplasia was similar with the national blood group frequencies. There was no statistically significant difference between all grades of glial neoplasia and healthy control patients. Median overall survival (mOS) of GBM patients are 12.9, 13.4, 5.7, 12.8 months in A, B, AB, and O blood groups, respectively (p = 0.46). mOS of anaplastic astrocytoma patients are 24.4, 47.2, 37.8, 29.2, 25.7 months, respectively (p = 0.96). mOS in grade1-2 astrocytoma in different blood groups are similar (p = 0.80).


In our small patient group, when compared with general population, there seems to be no association between frequencies of ABO blood groups and glial neoplasia. The ABO blood groups have no prognostic impact on glial neoplasia.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings